MedTrace Logo

Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease

NCT01075178 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2036

Last updated 2011-03-23

Study results available
· View outcomes & findings →

Summary

Retrospective medical record review study of specific adverse events in children with congenital heart disease who received palivizumab for prophylaxis of serious respiratory syncytial virus infection and control subjects that did not receive palivizumab

Conditions

  • Severe Respiratory Syncytial Virus Infection

Sponsors & Collaborators

Principal Investigators

  • Andrew Campbell, MD · Medical Director, Abbott Laboratories

Eligibility

Max Age
24 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Norway
  • Poland
  • Slovenia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075178 on ClinicalTrials.gov